



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/575,522	04/12/2006	Nafizal Hossain	06275-503US1	3659
26164 7590 05/23/2008 FISH & RICHARDSON P.C. P.O BOX 1022 MINNEAPOLIS, MN 55440-1022				
EXAMINER				
O'DELL, DAVID K				
ART UNIT		PAPER NUMBER		
1625				
MAIL DATE		DELIVERY MODE		
05/23/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/575,522

Applicant(s)

HOSSAIN, NAFIZAL

Examiner

David K. O'Dell

Art Unit

1625

Period for Reply -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 4/14/2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,2,5-10 and 12-18 is/are pending in the application.
- 4a) Of the above claim(s) 8,10 and 12-18 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,2,5-7 and 9 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/S508)
Paper No(s)/Mail Date _____

- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

1. Claims 1-2, 5-10, 12-18 are pending in the current application. Claims 1-2, 5-7, 9 are under examination. Claims 8, 10, 12-18 are withdrawn from consideration.
2. This is a National Stage of PCT/SE2004/001476, filed October 14, 2004, which claims priority to Swedish Application Serial No. 0302755-4, filed October 17, 2003.

Request for Continued Examination

3. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on April 14, 2008 has been entered.

Response to Remarks Arguments

4. Applicant's arguments filed April 14, 2007 have been fully considered but they are not persuasive. The rejections for scope of enablement are maintained as the directions for the preparation and use of the compounds commensurate in scope with the claims has not been provided. The number of examples provided by the specification are few and have been discussed previously (and are reproduced here again *vide infra*). The examiner (*vide infra* and in the previous actions) served to show the scope that is enabled by the specification, in terms of the compounds, and the teaching of the prior art. Apparently the applicant disagrees with the examiner's appraisal of the state of the art of medicinal chemistry, citing various case law examples to support the position. The examiner would like to clarify and provide other case law

contradictory to the applicant's citation and reiterate the rejection for not only "how to make" but also "how to use", both of which are requirements of 112 1st paragraph. The very limited disclosure and the inordinate amount of experimentation required to practice the invention, clearly warrant the conclusion made by the examiner, which was supported by references testifying to the state of the art and its unpredictability. While the examiner does believe that some of the compounds outside of those exemplified could at least be prepared synthetically by a skilled artisan, the paucity of working examples point to the key deficit in the disclosure, namely that undue experimentation would be required to practice the invention and that the "how to use" requirement has not been met. While organic chemistry is highly unpredictable, the degree of unpredictability in the pharmaceutical art is even greater. As one reviewer stated, Martin, Yvonne C. et. al. "Do Structurally Similar Molecules Have Similar Biological Activity?" *Journal of Medicinal Chemistry* **2002**, 45, 4350-4358:

"..... compounds that look very similar to a chemist sometimes bind in very different orientations in the protein active site, bind to a different conformation of a protein, or bind to a different protein altogether.¹⁵ In fact, such observations are why medicinal chemists need to make so many compounds to optimize the biological activity of a structural class, even when they are designing to a biological target of known structure...(pg. 4536 column 2, line 9).....This work also shows that the biological similarity is not so strong as has previously been assumed. For example, at ≥ 0.85 Tanimoto similarity in Daylight fingerprints, **only 30% of compounds similar to an active are themselves active.**"(conclusions) (H).

The examiner is not holding the applicant to a rigid scientific standard based in scientific fact, but rather the standard of patent law that the scope of the claims should be commensurate in scope with the invention disclosed. **Only five actual compounds are described in the specification.** Most of the groups recited in the instant claims are entirely prophetic. The

Art Unit: 1625

examiner submits that while modifications to the instantly claimed compounds are possible, this is an area that might be explored in future research, but has not been explored here. The determination of these relationships and the discovery of potent analogs is a different invention, and one that the applicant has not shown to be in possession of. While the examiner can do very little to reject small, modest changes such as the addition of a methyl group or halogen, the instant claims recite substituents that go far beyond even specious scientific reasoning. For example in claim 1, the following is a recitation for a group:

R^{10} represents a group C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_3 - C_6 cycloalkyl, adamantyl, C_5 - C_6 cycloalkenyl, phenyl or a saturated or unsaturated 5- to 10-membered heterocyclic ring system comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, each of which may be optionally substituted by one or more substituents independently selected from
nitro, hydroxyl, oxo, halogen, carboxyl, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkylthio,
 C_1 - C_6 alkylcarbonyl, C_1 - C_6 alkoxycarbonyl, phenyl and $-NHC(O)-R^{13}$, or

The only example is methyl. It appears that based upon the arguments of counsel defending such a claim that all of these groups are obvious over each other. The examiner does not believe this to be true. Regardless it is well known that molecular structure is correlated with physical properties and in particular in heterocyclic chemistry the change from one ring to another often results in dramatic changes in properties see Pozharskii et. al. Heterocycles in Life and Society Wiley, 1997, pgs. 1-6):

"It is rumored that the Russian scientist Beketov once compared heterocyclic molecules to jewelry rings studded with precious stones. Several carbon atoms thus make up the setting of the molecular ring, while the role of the jewel is played by an atom of another element, a heteroatom. In general, it is the heteroatom which imparts to a heterocycle its distinctive and sometimes striking properties."

The medicinal chemistry of chemokine receptors is relatively well-developed and many limitations are well known in the art. No trail is blazed to support the instantly claimed genus or guide the skilled artisan to some particular area where experimentation might take place. It is neither obvious nor predictable, to make such modifications.

In this case the claims bear no structural resemblance to the exemplified compounds, which are relatively homogenous and non-representative of the scope claimed. In order to practice the full scope of the invention, one of ordinary skill would not only need to create synthetic procedures *de novo*, but also decide what compounds to prepare. The specification gives literally no guidance with regard to what the requirements for activity are i.e. which substituents would be preferred. See *Ex parte Herzog, Hershberg, and Coan*, 115 USPQ 195 (Bd. Pat. App. & Int. 1956) affirming the examiner, and stating "it becomes obvious that the expressions defining the organic acids used.....are inclusive of inoperative materials and go far beyond the adequately disclosed subject matter of the specification." And also *Ex parte DIAMOND*, 123 USPQ 167 (Bd. Pat. App. & Int. 1959) where the examiner was affirmed for a scope of enablement rejection, and the court stated:

"the specification contains 23 specific examples, but it will be noted that they are to the preparation of relatively simple compounds.....This must be regarded as a relatively meagre and nonrepresentative disclosure to support claims which embrace millions of compounds. It should also be observed that appellant is working in a field where little prediction is possible and this Board has on several occasions held that the scope of claims should not be unduly extensive in fields where applicability is highly speculative or not explored and that subject matter which relies upon prediction for its support is unpatentable. *Ex parte Middleton*, 87 USPQ 57 ; *Ex parte Kauck et al.*, 95 USPQ 197 , *Ex parte Rosenkranz et al.*, Pat. No. 2,715,637. In *Minnesota Mining and Mfg. Co. et al. v. Carborundum Co. et al.*, 155 F.2d 746, 69 USPQ 288 , the court held that 'An inventor cannot disclose a small number of components which will serve as a springboard for claiming an entire class.'"

Art Unit: 1625

In addition *In re Fouché* 169 USPQ 429 dealt with a similar issue with respect to how to use requirement of 112 1st paragraph,

“Both the examiner and the board noted that none of the working examples pertained to compounds wherein Z was heterocyclic. Appellant is quite correct in contending that, under our decisions in *In re Robins*, 57 CCPA 1321, 429 F.2d 452, 166 USPQ 552 (1970), the inclusion of representative examples is not required to enable a person skilled in the art to use a generic invention. Nevertheless, an applicant must use some technique of providing teaching of how to use which is commensurate with the breadth of protection sought by the claim, unless such knowledge is already available to persons skilled in the art. It seems clear, and it is not disputed by appellant, that where an applicant undertakes to define his invention by the recitation of a Markush group, he must enable one skilled in the art to make and use at least one composition employing each member of the Markush group.”

See also: *Schering Corporation v. Gilbert et al.*, 68 USPQ 84 (2d Cir. 1946)

“Theoretically a multitude of substances not as yet found in nature and not as yet compounded could be synthesized, if skilled organic chemists were given the time and materials with which to work, and actually the formulas for them could be written. There is, however, a practical limit upon synthesis, though the extent of that is not fully known, for some of the new theoretical compounds might be impossible to create, and some would be so unstable that they would disintegrate either at once or in short periods of varying length. Moreover, while analogy is at times useful, organic chemistry is essentially an experimental science and results are often uncertain, unpredictable and unexpected.”

And *Nationwide Chemical Corporation, et al. v. Wright, et al.*, 192 USPQ 95 (M.D. Fla. 1976)

“with respect to generic claims to chemical and biological inventions, the scope of the claims is limited to what those skilled in the art could reasonably predict from the inventor's disclosure. This precept recognizes that one skilled in these chemical and biological arts cannot always reasonably predict how different chemical compounds and elements might behave under varying circumstances. Thus, in so-called “chemical” patent law practice, the claims of a patent are limited by the scope of what the disclosure reasonably teaches to one skilled in the art.”

In re Prutton, 96 USPQ 147 (C.C.P.A. 1952)

“The complete list of organic compositions includes, in generic form, most of the organic compounds found discussed in ordinary textbooks of organic chemistry..... It appears to be appellant's view that a selection of an unsaturated hydrocarbon from the first list and of a sulphide of phosphorus from the second list will provide support for the claims here under discussion. The Examiner holds, and properly we think, that the presentation of such lists from

Art Unit: 1625

which reagents may be selected is not a sufficient disclosure to support claims to a particular class of reaction product which might be produced by proper selection of reagents and determining the conditions of reaction.”

In re Walker, 22 USPQ (C.C.P.A. 1934)

“It is true, as argued by counsel, that appellant is entitled to claim not only the substance enumerated by him in his specification, but also their equivalents. However, in cases of this character, involving chemicals and chemical compounds, many of which of course differ radically in their properties, it must appear in the specification, either by the enumeration of a sufficient number of the members of a group or by other appropriate language, that “the chemicals or chemical combinations included therein were generally capable of accomplishing the desired result.” See *In re Ellis*, 37 App. D. C. 203; *In re Dosselman*, 37 App. D. C. 211; *In re Langmuir*, 20 C. C. P. A. (Patents) 733, 62 F. (2d) 93.”

In Re Sus and Schaefer 134 USPQ 1962 301-310 (*affirmed*):

“It is, however, consistent with this public purpose embodied in the pertinent statutory requirement that the *invention claimed* shall be no broader than the *invention set forth* in the written description forming a part of the specification.....thus it seems to us that one killed in this art would not be taught by written description of the invention in the specification that any 'aryl or substituted aryl radical' would be suitable for the purposes of the invention but rather that only *certain aryl radicals* and certain specifically substituted aryl radicals would be suitable for such purposes.” Emphasis in Original.

The examiner has more than made his case for the enablement rejection. The double patenting rejection is maintained for the reasons of record in some instances, and withdrawn in the divisional application since the applicant has submitted amended claims.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference

Art Unit: 1625

claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.


Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

5. Claims 1-2, 5-7, 9 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-8, 10 of copending Application No. 10/579,545 in view of Xue et. al. U.S. Pre-Grant Publication 2006/0252751. The analysis applied in this action at 4 applies here. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:


Determination of the scope and content of the prior art


(MPEP 2141.01)

Xue et. al. teaches spiro[benzofuran-2,1'-cyclohexan]-4'-amines that are chemokine antagonists. 10/579,545 teach spiro[benzofuran-2,4'-piperidines bearing a 1-phenoxy-3-propan-2-ol substituent on the piperidiny nitrogen atom. This relationship is illustrated graphically in Figure 1.




Some of the compounds disclosed by Xue are show below:





***Ascertainment of the difference between the prior art and the claims
(MPEP 2141.02)***

Hossain, Nafizal; Ivanova, Svetlana & Mensonides-Harsema, Marguerite do not expressly teach the compounds of the instant case, however the only difference between these compounds is the presence of a methylene group. By inserting a what is formally a methylene (CH₂ actually CH in the ring and H on N) into the compounds of Hossain, Nafizal; Ivanova, Svetlana & Mensonides-Harsema, Marguerite a spiro[benzofuran-2,1'-cyclohexan]-4'-amine is produced, which is a core pharmacophore of chemokine antagonism. These relationships are illustrated graphically in Figure 2.



Finding of prima facie obviousness

***Rational and Motivation
(MPEP 2142-2143)***

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to prepare the compounds of the instant case. The compounds of the claims at hand are analogs of old compounds. One of ordinary skill would be motivated to make the compounds of the invention because he would expect the compounds to have similar properties, indeed we see that these compounds have the same properties. A reference is good not only for what it teaches by direct anticipation but also for what one of ordinary skill in the art might reasonably infer from the teachings. (*In re Opprecht* 12 USPQ 2d 1235, 1236 (Fed Cir. 1989); *In re Bode* 193 USPQ 12 (CCPA) 1976). In light of the forgoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103(a). From the teachings of the references, it is apparent that one of

ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary. *In re Grabiak* 226 USPQ 870, "[w]hen chemical compounds have "very close" structural similarities and similar utilities, without more a *prima facie* case may be made", *In re Deuel* 34 USPQ2d 1210, "a known compound may suggest its **analog**s or isomers, either geometric isomers (*cis v. trans*) or position isomers (emphasis added) (*e.g. ortho v. para*)".

This is a provisional obviousness-type double patenting rejection.

6. Claims 1-2, 5-7, 9 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-10, 12 of copending Application No. 10/581,171 in view of Xue et. al. U.S. Pre-Grant Publication 2006/0252751. The analysis applied in this action at 5 applies here. This is a provisional obviousness-type double patenting rejection.

7. Claims 1-2, 5-7, 9 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-10, 12, 14 of copending Application No. 10/583,468 in view of Xue et. al. U.S. Pre-Grant Publication 2006/0252751. The analysis applied in this action at 5 applies here. Although claim 9 is apparently a claim for "a claim".

8. Claims 1-2, 5-7, 9 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-9, 13 of copending Application No. 10/520,699 in view of Xue et. al. U.S. Pre-Grant Publication 2006/0252751. The analysis applied in this action at 5 applies here.

Art Unit: 1625

This is a provisional obviousness-type double patenting rejection.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

9. Claims 1-2, 5-6, 9 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for certain compounds, does not reasonably provide enablement for the protracted list of compounds bearing the protracted list of substituents. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make or use the invention commensurate in scope with these claims. There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is “undue.” These factors include, but are not limited to the following:

- (A) *The breadth of the claims;*
- (B) *The nature of the invention;*
- (C) *The state of the prior art;*
- (D) *The level of one of ordinary skill;*
- (E) *The level of predictability in the art;*
- (F) *The amount of direction provided by the inventor;*
- (G) *The existence of working examples; and*
- (H) *The quantity of experimentation needed to make or use the invention*

In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).

(A) The breadth of the claims: The claims are very broad encompassing a variety of compounds, bearing multiple substitutions **(B) The nature of the invention:** This is a chemical invention requiring the synthesis of compounds. **(D) The level of one of ordinary skill:** One of ordinary skill is a practicing organic chemist. **(C) The state of the prior art:** Little prior art

exists on these complex compounds, however the synthesis will be evaluated on what is known using scientific principles. **(E) The level of predictability in the art:** Chemistry is unpredictable. See *In Re Marzocchi and Horton* 169 USPQ at 367 paragraph 3. As stated in the preface to a recent treatise:

“Most non-chemists would probably be horrified if they were to learn how many attempted syntheses fail, and how inefficient research chemists are. The ratio of successful to unsuccessful chemical experiments in a normal research laboratory is far below unity, and synthetic research chemists, in the same way as most scientists, spend most of their time working out what went wrong, and why. Despite the many pitfalls lurking in organic synthesis, most organic chemistry textbooks and research articles do give the impression that organic reactions just proceed smoothly and that the total synthesis of complex natural products, for instance, is maybe a labor-intensive but otherwise undemanding task. In fact, most syntheses of structurally complex natural products are the result of several years of hard work by a team of chemists, with almost every step requiring careful optimization. The final synthesis usually looks quite different from that originally planned, because of unexpected difficulties encountered in the initially chosen synthetic sequence. Only the seasoned practitioner who has experienced for himself the many failures and frustrations which the development (sometimes even the repetition) of a synthesis usually implies will be able to appraise such work.....Chemists tend not to publish negative results, because these are, as opposed to positive results, never definite (and far too copious).....” Dorwald F. A. *Side Reactions in Organic Synthesis*, 2005, Wiley: VCH, Weinheim pg. IX of Preface.

Art Unit: 1625

(F) The amount of direction provided by the inventor, (G) The existence of working examples, and (H) The quantity of experimentation needed to make or use the invention:

The examiner will first consider the Markush structure I of claim 1, and discuss the limitations inherent to the paucity of available starting materials, as well as the inherent limitations of the chemistry used to prepare the examples. As per MPEP:


As per MPEP:

A key issue that can arise when determining whether the specification is enabling is whether the starting materials or apparatus necessary to make the invention are available.

In the biotechnical area, this is often true when the product or process requires a particular strain of microorganism and when the microorganism is available only after extensive screening. The Court in *In re Ghiron*, 442 F.2d 985, 991, 169 USPQ 723, 727 (CCPA 1971), made clear that if the practice of a method requires a particular apparatus, the application must provide a sufficient disclosure of the apparatus if the apparatus is not readily available. The same can be said if certain chemicals are required to make a compound or practice a chemical process. *In re Howarth*, 654 F.2d 103, 105, 210 USPQ 689, 691 (CCPA 1981).


The synthetic route and starting materials that the applicant has provided to make the scope of this invention has been reproduced below as Scheme1:

Art Unit: 1625



The key materials here are the α -bromo-2-fluoro-toluene derivative **1**, the N-Boc-4-amino cyclohexanone **2**, phenols such as **8** bearing amide groups, and glycidols **9**. A search for each of these materials in the Aldrich Chemical Company catalog (St. Louis, MO) was conducted, the results of which are reproduced below:

Art Unit: 1625



Enter Search Criteria

Search Type:

Structure:

JME Editor courtesy of Peter Ertl, Novartis

SMILES:

MW:

Results / Page:

Total Hits:
















[More Options](#)

Search Results: 1-15 of 16 matches [New Search](#)

Sort By:


MW	Compound Properties	Structure	Add	Prod. #	Purity
Name:	2-Fluorobenzyl bromide	Structure			
IUPAC:	1-(bromomethyl)-2-fluorobenzene	Score:100		209511	98%
MF:	C ₇ H ₆ BrF				
CAS #:	446-48-0				
MW:	189.02				
MDL #:	MFCD0090324				
BP:	84 - 85 °C				
FP:	181				
d:	1.5670				

Art Unit: 1625

Name: 2,6-Difluorobenzyl bromide IUPAC: 2-(bromomethyl)-1,3-difluorobenzene MF: C ₇ H ₅ BrF ₂ CAS #: <u>85118-00-9</u> MW: 207.02 MDL #: <u>MFCD00000329</u> FP: 230	Score: 96 	 <u>85141</u> purum,  <u>264431</u> ≥95.0% (GC) 97%
Name: 2,5-Difluorobenzyl bromide IUPAC: 2-(bromomethyl)-1,4-difluorobenzene MF: C ₇ H ₅ BrF ₂ CAS #: <u>85117-99-3</u> MW: 207.02 MDL #: <u>MFCD00009897</u> FP: 60 d: 1.6090	Score: 84 	 <u>264423</u> 98%
Name: 2,3-Difluorobenzyl bromide IUPAC: 1-(bromomethyl)-2,3-difluorobenzene MF: C ₇ H ₅ BrF ₂ CAS #: <u>113211-94-2</u> MW: 207.02 MDL #: <u>MFCD00042488</u> FP: 194 d: 1.6280	Score: 86 	 <u>68318</u> ≥99.5% (GC)  <u>74259</u> purum,  <u>265314</u> ≥99.5% (GC) 98%
Name: 2,4-Difluorobenzyl bromide IUPAC: 1-(bromomethyl)-2,4-difluorobenzene MF: C ₇ H ₅ BrF ₂ CAS #: <u>23915-07-3</u> MW: 207.02 MDL #: <u>MFCD00011649</u> FP: 104 d: 1.6130	Score: 90 	 <u>264415</u> 98%
Name: 2-Chloro-6-fluorobenzyl bromide IUPAC: 2-(bromomethyl)-1-chloro-3-fluorobenzene MF: C ₇ H ₅ BrClF CAS #: <u>68220-26-8</u> MW: 223.47 MDL #: <u>MFCD00040126</u> FP: 230 d: 1.6290	Score: 69 	 <u>539020</u> 96%
Name: 2,3,6-Trifluorobenzyl bromide IUPAC: 2-(bromomethyl)-1,3,4-trifluorobenzene MF: C ₇ H ₄ BrF ₃ CAS #: <u>151412-92-1</u>	Score: 84 	 <u>440407</u> 97%

Art Unit: 1625


>MW: 225.01
MDL #: [MFCD00061208](#)
BP: 114 °C
FP: 195
d: 1.7180

[Zoom In](#)

Score:81

[554685](#) 97%


Name: 2,3,4-Trifluorobenzyl bromide
IUPAC: 1-(bromomethyl)-2,3,4-trifluorobenzene
MF: $C_7H_4BrF_3$
CAS #: [157911-55-2](#)
>MW: 225.01
MDL #: [MFCD00061233](#)
FP: 195
d: 1.71

[Zoom In](#)

Score:80

[556491](#) 97%


Name: 1-Bromomethyl-4-methyl-2,3,5,6-tetrafluorobenzene
IUPAC: 1-(bromomethyl)-2,3,5,6-tetrafluoro-4-methylbenzene
MF: $C_8H_4BrF_4$
CAS #: [92814-00-1](#)
>MW: 257.02
MDL #: [MFCD03091155](#)
FP: 199

[Zoom In](#)

Score:67

[539627](#) 98%


Name: 2-Fluoro-6-(trifluoromethyl)benzyl bromide
IUPAC: 2-(bromomethyl)-1-fluoro-3-(trifluoromethyl)benzene
MF: $C_8H_5BrF_4$
CAS #: [239087-08-2](#)
>MW: 257.02
MDL #: [MFCD00082477](#)
FP: 225

[Zoom In](#)

Score:66

[538094](#) 97%

Name: 2-Fluoro-3-(trifluoromethyl)benzyl bromide
IUPAC: 1-(bromomethyl)-2-fluoro-3-(trifluoromethyl)benzene
MF: $C_8H_5BrF_4$
CAS #: [184070-25-0](#)
>MW: 257.02
MDL #: [MFCD00061172](#)

[Zoom In](#)


Score:81

[17910](#) puriss., ≥99.0% (GC)
 [101052](#) 99%
 [33001](#) ampoule of 5 g

Name: 2,3,4,5,6-Pentafluorobenzyl bromide
IUPAC: 1-(bromomethyl)-2,3,4,5,6-pentafluorobenzene
MF: $C_6H_4BrF_5$
CAS #: [1765-40-8](#)
>MW: 260.99
MDL #: [MFCD00000299](#)
BP: 174 - 175 °C

Art Unit: 1625

FP: 181
d: 1.7280




Zoom In

Name: 4-bromo-2-fluorobenzyl bromide
IUPAC: 4-bromo-1-(bromomethyl)-2-fluorobenzene
MF: $C_7H_5Br_2F$
CAS #: [76283-09-5](#)
MW: 267.92
MDL #: [MECD00055467](#)

Score:72


477559 98%



Zoom In

Name: 2,3,5,6-Tetrafluoro-4-(trifluoromethyl)benzyl bromide
IUPAC: 1-(bromomethyl)-2,3,5,6-tetrafluoro-4-(trifluoromethyl)benzene
MF: $C_8H_2BrF_7$
CAS #: [76437-40-6](#)
MW: 310.99
MDL #: [MECD000191855](#)
FP: 210
d: 1.8640


Score:60

 87285 purum, $\geq 97.0\%$ (GC)
 406406 98%


Zoom In

Name: DECAFLUOROBENZHYDRYL BROMIDE
IUPAC: DECAFLUOROBENZHYDRYL BROMIDE
MF: $C_{13}HBrF_{10}$
CAS #: [5736-49-2](#)
MW: 427.04
MDL #: [MECD00017901](#)


Score:51





Zoom In

Most disturbingly we do not find the 5-chloro derivative which is required to synthesize all of the compounds that were actually made. We can see that R_1 can be nothing but fluoro, trifluoromethyl or chloro.

Art Unit: 1625

SIGMA-ALDRICH Name 


Search 


Enter Search Criteria  Hide Criteria

Search Search on results CLEAR

Search Type: SubStructure (2D)

Structure:





JME Editor courtesy of Peter Ertl, Novartis

SMILES: Load

MW: Between &

Results / Page: 50

Total Hits: 100

[More Options](#)

SYNTHEMATIX
www.synthematrix.com



No such cyclohexanones appear to be commercially available. While many phenols such as **8** are commercial, it would appear that the amide functionality (reverse as well) is required for activity, based on the fact that applicant has no examples of compounds that are not amides (in the ortho position) and the fact that Xue et. al. (*supra*) require the amide moiety for antagonism. To the examiners knowledge only one nosylglycidol, namely compound **9**, is commercial. Substituents should be limited to lower alkyl.

According to the U.S. Court of Customs and Patent Appeals in *In re Argoudelis, De Boer, Eble, and Herr* 168 USPQ 99 at 101, "[o]rdinarily no problem in this regard arises since the method of preparing almost all starting materials can be set forth in writing if the materials are not already known and available to the workers in the art, and when this is done the specification is enabling to the public". *In re Argoudelis, De Boer, Eble, and Herr* 168 USPQ 99 at 104, "it is essential that there be no question that, *at the time an application for patent is filed*, (emphasis in original) the invention claimed therein is fully capable of being reduced to practice (i.e., that no technological problems, the resolution of which would require more than ordinary skill and reasonable time, remain in order to obtain an operative, useful embodiment)." That is not the situation here. Rather we find no direction as to how the many required starting materials of formula **1**, **2**, **8**, and **9** are to be obtained. Where may the directions to prepare or buy them be found?

In re Howarth, 210 USPQ 689, (claimed derivatives of clavulanic acid not enabled by specification lacking information of how prepare the clavulanic acid or directions to reference

Art Unit: 1625

materials containing such information), *Ex parte Schwarze* 151 USPQ 426 (where starting material is not known to art as of date of filing application, there must be included a description of preparation thereof to enable one skilled in this art to carry out applicant's invention), *Ex parte Moersch* 104 USPQ 122 (claims to process for the production of (1)-yl-p-nitrophenyl-2-dichloroacetamido-propane-1,3-diol not enabled because of failure to describe source or method of obtaining starting compound; although starting compound is identified by means of appropriate name and by structural formula). If such starting materials could be obtained compounds could be obtained it is very clear that the protracted list of substituents for R¹ cannot undergo the synthetic procedures given. Nitriles and other electrophiles will also undergo addition by Grignards (Jie Jack Li *Name Reactions A Collection of Detailed Reaction Mechanisms* "Grignard Reaction" Third Expanded Edition Springer 2006, pg. 271-272. Metal halogen exchange between a ("halo") like iodine and a Grignard will also occur (Knochel et. al. *Angew. Chem. Int. Ed.* **2003**, 42, 4302 –4320). The "alkylhalo" compounds will undergo metal halogen exchange when in the presence of a Grignard (Knochel *ibid.*). The applicant has argued that protecting groups may be used to overcome these limitations, however there are no protecting groups for nitrile or halogen or nitro. How does one protect a halogen, nitrile, or a nitro group?

For guidelines on the relationship of working examples and the size of claimed genus see the MPEP 2164:

WORKING EXAMPLES AND A CLAIMED GENUS For a claimed genus, representative examples together with a statement applicable to the genus as a whole will ordinarily be sufficient if one skilled in the art (in view of level of skill, state of the art and the information in the specification) would expect the claimed genus could be used in that manner without undue experimentation. Proof of enablement will be required for other members of the claimed genus only where adequate reasons are advanced by the

Art Unit: 1625

examiner to establish that a person skilled in the art could not use the genus as a whole without undue experimentation.

2164.03 Relationship of Predictability of the Art and the Enablement Requirement

[R-2] The amount of guidance or direction needed to enable the invention is inversely related to the amount of knowledge in the state of the art as well as the predictability in the art. *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). The “amount of guidance or direction” refers to that information in the application, as originally filed, that teaches exactly how to make or use the invention. The more that is known in the prior art about the nature of the invention, how to make, and how to use the invention, and the more predictable the art is, the less information needs to be explicitly stated in the specification. In contrast, if little is known in the prior art about the nature of the invention and the art is unpredictable, the specification would need more detail as to how to make and use the invention in order to be enabling. >See, e.g., *Chiron Corp. v. Genentech Inc.*, 363 F.3d 1247, 1254, 70 USPQ2d 1321, 1326 (Fed. Cir. 2004) (“Nascent technology, however, must be enabled with a ‘specific and useful teaching.’ The law requires an enabling disclosure for nascent technology because a person of ordinary skill in the art has little or no knowledge independent from the patentee’s instruction. Thus, the public’s end of the bargain struck by the patent system is a full enabling disclosure of the claimed technology.” (citations omitted)).< The “predictability or lack thereof” in the art refers to the ability of one skilled in the art to extrapolate the disclosed or known results to the claimed invention. If one skilled in the art can readily anticipate the effect of a change within the subject matter to which the claimed invention pertains, then there is predictability in the art. On the other hand, if one skilled in the art cannot readily anticipate the effect of a change within the subject matter to which that claimed invention pertains, then there is lack of predictability in the art. Accordingly, what is known in the art provides evidence as to the question of predictability. In particular, the court in *In re Marzocchi*, 439 F.2d 220, 223-24, 169 USPQ 367, 369-70 (CCPA 1971), stated:

[I]n the field of chemistry generally, there may be times when the well-known unpredictability of chemical reactions will alone be enough to create a reasonable doubt as to the accuracy of a particular broad statement put forward as enabling support for a claim. This will especially be the case where the statement is, on its face, contrary to generally accepted scientific principles. Most often, additional factors, such as the teachings in pertinent references, will be available to substantiate any doubts that the asserted scope of objective enablement is in fact commensurate with the scope of protection sought and to support any demands based thereon for proof. [Footnote omitted.]

The scope of the required enablement varies inversely with the degree of predictability involved, but even in unpredictable arts, a disclosure of every operable species is not required. A single embodiment may provide broad enablement in cases involving predictable factors, such as mechanical or electrical elements. *In re Vickers*, 141 F.2d 522, 526-27, 61 USPQ122, 127 (CCPA 1944); *In re Cook*, 439 F.2d 730, 734, 169 USPQ 298, 301 (CCPA 1971). However, in applications directed to inventions in arts where the results are unpredictable, the disclosure of a single species usually does not provide an adequate basis to support generic claims. *In re Soll*, 97 F.2d 623, 624, 38 USPQ 189, 191 (CCPA 1938). In cases involving unpredictable factors, such as most chemical reactions and physiological activity, more may be required. *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970) (contrasting mechanical and electrical elements with chemical reactions and physiological activity). See also *In re Wright*, 999 F.2d 1557, 1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993); *In re Vaecck*, 947 F.2d 488, 496, 20 USPQ2d 1438,

1445 (Fed. Cir.1991). This is because it is not obvious from the disclosure of one species, what other species will work.

Another disturbing feature of what is before the examiner, is the fact that it appears that no assays were performed. These compounds may perform in this assay however this has not been asserted. There is no support in the specification for the use of these compounds as chemokine antagonists. While applicant states on pg. 40 "Compounds are evaluated by their ability to depress the chemotactic response to a standard concentration of MIP-1 α chemokine." No evidence is given that these compounds actually were shown to have this activity. Given that similar compounds have the activity we can surmise that the exemplified compounds might have this activity (supra double patenting rejection). The assumption that a chemokine receptor is involved may be incorrect, given that agonism at other GPCRs (δ -opioid receptors for instance), can lead to down regulation of chemokine receptors via heterodimers or higher oligomer complex formation (Chen et. al. *European Journal of Pharmacology* **2004**, 483, 175-186.). The complete receptor profile of THP-1 cells is not known. Applicant may consider a binding assay as in Carroll et. al. WO 00/014086 cited by applicant ref. AG pg. 34:

TABLE 1
The activities of test compounds are reported in the
10 Table below as IC₅₀ values or the inhibitor concentration
required for 50% inhibition of specific binding in receptor
binding assays using ¹²⁵I-RANTES or ¹²⁵MIP-1 α as ligand and
THP-1 cell membranes. Specific binding is defined as the
total binding minus the non-specific binding; non-specific
15 binding is the amount of cpm still detected in the presence
of excess unlabeled Rantes or ¹²⁵MIP-1 α .

or Bondinell et. al. WO 01/64213 A1 pg. 23-25 cited by applicant ref. AH

Art Unit: 1625

25 Biological Data:CCR5 Receptor Binding Assay

CHO cell membranes (0.25×10^6 cell equivalents) derived from CHO cells stably transfected with CCR5 were incubated with $0.3 \text{ }^{125}\text{I}$ -RANTES in a 96 well plate for 45 min. at room temperature (final reaction volume 200 μl). The reaction was

- 30 terminated by filtration and the filters (GF/C) were washed twelve times with a solution of phosphate buffered saline containing 0.1 % bovine serum albumin and 0.05 % NaN_3 . The radioactivity bound to filters was measured by liquid scintillation spectrometry. Non-specific binding was determined in the presence of unlabelled RANTES (10 or 30 nM) and averages 30-50% of total binding.

Art Unit: 1625

*v

CCR5 Receptor Functional Assay

- The cellular functional assay used to assess antagonist activity of compounds was RANTES-induced Ca^{2+} mobilization in RBL 2H3 cells stably expressing the hCCR5 or mCCR5 receptor (RBL 2H3 hCCR5). Agonist activity is determined by
- 5 Ca^{2+} mobilization in the same cells which is inhibitable by a selective CCR5 antagonist. Cells were grown to 80-100% confluency in T-150 flasks and washed with phosphate-buffered saline. Cells were lifted from the flasks by treating with 3 mL of 1 mM EDTA for 3 min. at room temperature and diluting to 2×10^6 cells/mL with Krebs Ringer Henseleit buffer (KRH; 118 mM NaCl, 4.6 mM KCl, 25 mM
- 10 NaHCO_3 , 1 mM KH_2PO_4 and 11 mM glucose) containing 5 mM HEPES (pH 7.4), 1 mM CaCl_2 , 1 mM MgCl_2 and 0.1% BSA and centrifuged at 200g for 3 min. Cells were resuspended at 2×10^6 cells/mL in the same buffer with 2 μM Fura-2AM, and incubated for 35 min. at 37° C. Cells were centrifuged at 200 x g for 3 min. and resuspended in the same buffer without Fura-2AM, then incubated for 15 min. at
- 15 37° C to complete the hydrolysis of intracellular Fura-2AM, and then centrifuged as before. Cells (10^6 cells/mL) were resuspended in cold KRH with 5 mM HEPES (pH 7.4), 1 mM CaCl_2 , 1 mM MgCl_2 and 0.1% gelatin and maintained on ice until assayed. For antagonist studies, aliquots (2 mL) of cells were prewarmed at 37° C for 5 min. in 3 mL plastic cuvettes and fluorescence measured in a fluorometer
- 20 (Johnson Foundation Biomedical Group, Philadelphia, PA, USA) with magnetic stirring and temperature maintained at 37° C. Excitation was set at 340 nm and emission set at 510 nm. Various concentrations of antagonists or vehicle were added and fluorescence monitored for ~15 sec to ensure that there was no change in baseline fluorescence, followed by the addition of 33 nM RANTES. Maximal Ca^{2+}
- 25 attained after 33 nM RANTES stimulation was calculated as described by Grynkiewicz *et al.*, (1985). The percent of maximal RANTES-induced Ca^{2+} was determined for each concentration of antagonist and the IC_{50} , defined as the concentration of test compound that inhibits 50% of the maximal 33 nM RANTES response, obtained from the concentration-response curves (5-7 concentrations of
- 30 antagonists). Alternatively, this CCR5 receptor functional assay was performed on murine CCR5 (mCCR5) with a RANTES concentration of 2nM.

The compounds of this invention show CCR5 receptor modulator activity having IC_{50} values in the range of 0.0001 to 100 μM . The full structure/activity relationship has not yet been established for the compounds of this invention.


- 35 However, given the disclosure herein, one of ordinary skill in the art can utilize the present assays in order to determine which compounds of formula (I) are modulators

Art Unit: 1625

The applicant regards these compounds as CCR5 antagonists. However MIP-1 α is a ligand for both CCR1, CCR3 and CCR5, see Thomson et. al. The Cytokine Handbook 4th Ed. Academic: New York **2003**, 1084-1087. It is unclear which receptors these compounds are binding to, or if they are in fact ligands for all three. Regardless, structural requirements for chemokine binding to CCR1, CCR3, and CCR5 are stringent as is well known the art. In the field of CCR1 antagonists many limitations are well known in the art. These compounds are sensitive to structural changes that may be relatively minor in the chemical sense, see Xie, et. al. "Identification of novel series of human CCR1 antagonists," *Bioorganic & Medicinal Chemistry Letters* **2008**, 18, 2215-2221.

"Compound **63**, where the positions of the halogens were switched, retained comparable potency (**63** vs. **61**) suggesting the importance of 4-halogen on the phenyl ring. By contrast, replacement of the 4-chloro with the bulky tBu (**65**) and phenyl (**66**) groups resulted in total loss of affinity, suggesting a space restriction around this site. All other substituents (for example, OMe, SMe and OPh) led to inactive compounds."

Table 6. SAR of substitution on the left aromatic in the 1, 4'-bipiperidin-4-ol linker series

Compound	R		
		CCR1 binding ^a IC ₅₀ , μ M	Ca ²⁺ flux ^b IC ₅₀ , μ M
65	4-tBu	>10	>10
66	4-Ph	>10	>10
67	4-OMe	>10	>10
68	4-SMe	>10	7.98


Art Unit: 1625

In fact many substituents are not tolerated at all, resulting in “a total loss of affinity.” (C) (E)

As further of evidence of the extreme unpredictability in the CCR1 antagonist development art see Brown et. al. “Novel CCR1 antagonists with improved metabolic stability”

Bioorganic & Medicinal Chemistry Letters **2004**, 14, 2175–2179:

“Exploration of the C-5 position revealed that a number of halobenzyl C-5 substituents imparted a significant improvement in potency. Most notably, the 3-fluorobenzyl analogue 6j was shown to be >10-fold more potent than the desfluoro analogue 6b and also retained excellent HLM stability. Interestingly, the SAR in this region of the molecule was quite sensitive to minor structural changes. For example, while the 3-fluorobenzyl analogue 6j showed good potency, the closely related 4-fluorobenzyl analogue 6k was inactive.”




Compound	R ¹	R ²	R ³	CCR3 binding IC ₅₀ (μM)	CCR3 chemotaxis IC ₅₀ (μM)
6i	2-Fluorophenyl		-NH ₂	0.052	0.68
6j	3-Fluorophenyl		-NH ₂	0.046	0.065
6k	4-Fluorophenyl		-NH ₂	>25	>25

Here it is very clearly shown that what appears to a relatively innocuous change results in compounds with no activity. (C) (E)

CCR3 activity is also highly dependent upon the structure of the compound in particular N-Benzyl piperidines are well-known to have limitations on the substituents on the phenyl ring, see Ting et. al. “The synthesis of substituted bipiperidine amide compounds as CCR3 ligands: Antagonists versus agonists” *Bioorganic & Medicinal Chemistry Letters* **2005** 15, 3020–3023:

"The monosubstituted 2-chloro analogue 11c is inactive while the 4-chloro analogue 11d shows reasonable CCR3 affinity. The saturated cyclohexylmethyl analogue 11e is completely inactive. Methyl substitution at the benzylic position as in 11f or extension to the 3,4-dichlorophenethyl as in 11g also decrease affinity. Replacement of the 3,4-dichlorobenzyl moiety with the corresponding varimide moieties as in compounds 11h and 11i or the urea moiety as in compound 11j also produces inactive analogues."

Table 2. In vitro CCR3 membrane binding and agonist (GTP γ S) activity of benzyl bipiperidine analogues **4i** and **11a-j**



Compd	R	K_i (nM)	$E_{\max}^{\%}$ GTP γ S ^a
4i	3,4-DiCl-PhCH ₂	23 \pm 1	-7
11a	3,5-DiCl-PhCH ₂	398 \pm 59	45
11b	2,5-DiCl-PhCH ₂	391 \pm 44	45
11c	2-Cl-PhCH ₂	36% ^a	NT
11d	4-Cl-PhCH ₂	95 \pm 7	-8
11e	CyclohexylCH ₂	17% ^b	NT
11f	3,4-DiCl-PhCHMe	74 \pm 3	-12
11g	3,4-DiCl-PhCH ₂ CH ₂	180 \pm 32	2
11h	3,4-DiCl-PhCO	20% ^b	NT
11i	3,4-DiCl-PhCH ₂ CO	767 \pm 16	NT
11j	3,4-DiCl-PhNHCONH	6% ^b	NT

NT = not tested.

^a $E_{\max}^{\%}$ at 10 μ M ($n = 2$).

^b % inhibition at 1 μ M ($n = 2$).

It is quite notable that all the compounds of the instant case have a dichlorophenyl moiety in the position corresponding to the R of Table 2 of Ting.

For CCR5 ligands many limitations are well known in the art. In a study of similar compounds Thoma, et. al. "Orally Bioavailable Competitive CCR5 Antagonists" *Journal of Medicinal Chemistry* **2004**, 47, 1939-1955, made the following statement, about substituents on the phenyl rings:

"First we explored a few analogues of the highly potent CCR5 antagonist 1a with a cyano substituent in different positions of the benzyl group (Table 1). The 3-substituted compound 1c was found to be even more potent than unsubstituted 1a on both human and cyno CCR5. The 2-substituted derivative 1b was significantly less potent than 1a in the human binding assay but highly inferior in the Ca²⁺-mobilization assay. In addition, it was found to be almost inactive on cyno CCR5. The 4-substituted derivative 1d was considerably less potent than 1c. Compound 1e with a trimethoxybenzyl group was found to be completely inactive. These findings suggest that substituents of the benzyl group are well tolerated in the 3-position but can significantly reduce the affinity when attached to other ring positions. Furthermore, the substitution pattern seems to affect the reactivity on human vs cyno CCR5." Pg. 1941 (C & E)

Thus it is clear that substitution can have a very pronounced impact on the active pharmacophore, and a choice of the wrong substituent or too many substituents gives compounds with no activity. The claims here may have many substituents most of which are prophetic. All the working examples have very limited substituents.

We have been given no information in regard to the molecular determinants of chemokine inhibition for the compounds of the instant case. (F & G) The factors outlined in *In Re Wands* mentioned above apply here, and in particular as per the MPEP 2164.01 (a): "A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled

in the art how to make and/or use the full scope of the claimed invention without undue experimentation. In re Wright 999 F.2d 1557,1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993).” It is very clear that one could not make/use this very broad invention that has only two working examples in this unpredictable art without undue experimentation. **(C, E, F, G, H).**

Conclusion

10. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to David K. O'Dell whose telephone number is (571)272-9071. The examiner can normally be reached on Mon-Fri 7:30 A.M.-5:00 P.M EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on (571)-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Art Unit: 1625

D.K.O.

/Rita J. Desai/
Primary Examiner, Art Unit 1625